Crofelemer in Cancer

Crofelemer in Cancer

Cancer Therapy–related Diarrhea

World icon

9.8 million people
receive chemotherapy worldwide per year1

Intestine Icon

Chemotherapy-induced
diarrhea occurs in
50%-80%
of treated patients2

40% of people icon

Patients with cancer therapy–
related diarrhea (CTD) were
40% more likely to
discontinue chemotherapy or
targeted cancer therapy than
patients without CTD3

Crofelemer is an oral agent that relieves diarrhea through normalizing fluid and electrolyte balance in the GI tract

Research & Development

In October 2020, Napo Pharmaceuticals initiated a pivotal Phase 3 clinical trial for which enrollment is ongoing

Pipeline Icon

This Phase 3 study is evaluating crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy

Cancer Center Icon

The principal investigator and co-investigators identified are from MD Anderson Cancer Center

Learn About OnTarget Trial
Become an OnTarget Trial Investigator

References: 1. Wilson B, Jacob S, Yap M, et al. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study. Lancet Oncol. 2019;20(6):769-780. doi:10.1016/S1470-2045(19)30163-9 2. Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51-63. doi:10.1177/1758834009355164 3. Okhuysen PC, Schwartzberg LS, Roeland E, et al. The impact of cancer-related diarrhea on changes in cancer therapy patterns. J Clin Oncol. 2021;39(15):12111. doi:10.1200/JCO.2021.39.15_suppl.12111